- Open Access
Possible changes in the transmissibility of trachoma following MDA and transmission reduction: implications for the GET2020 goals
© Gambhir and Pinsent. 2015
- Received: 29 August 2015
- Accepted: 2 October 2015
- Published: 22 October 2015
The role of mass drug administration (MDA) and the implementation of transmission reduction measures are essential to successfully control and eliminate a wide range of NTDs, including the ocular disease trachoma. Immunity to trachoma infection acts by reducing the duration of an individual’s infectious period and by reducing their infectivity with each successive infection.
In this study, we use a model of trachoma infection, which includes population immunity, to explore the impact of treatment and transmission reduction measures on trachoma prevalence. Specifically, we investigate the possibility of increasing transmissibility of trachoma arising as MDA and transmission reduction measures are scaled up in endemic settings.
We demonstrate this increase in transmissibility by calculating the effective reproduction number during several simulated control programmes and show that it is related to a decrease in the level of immunity in the population.
This effect should be studied in the field by measuring the rate of return of infection and disease in at least two separate age groups. If the decline of population immunity is operating, it should be accounted for when planning for the GET2020 goal of eliminating blinding trachoma by 2020.
- Reproduction number
Infection with ocular Chlamydia trachomatis (trachoma) remains the world’s leading infectious cause of blindness. It is endemic in 53 countries, with an estimated 84 million visually impaired and in need of treatment, while 1.2 million individuals are irreversibly blind . The World Health Organization (WHO) recommends the use of the SAFE strategy to help with trachoma control (Surgery, Antibiotics, Facial cleanliness, and Environmental changes). Furthermore, it is estimated that 110 million people inhabit areas in which trachoma is believed to be endemic, and where the SAFE strategy needs to be implemented . The WHO advocates eliminating blinding trachoma by 2020, and the Global Alliance for the Elimination of Trachoma by 2020 was established to help achieve this goal. The first GET2020 goal aims to reduce trachomatous inflammation follicular (TF) prevalence to <5 % in all 1–9 year olds by 2020. Reduced prevalence of active disease will only be maintained if transmission is reduced sufficiently, and this relies on the successful implementation of antibiotic treatment as well as long term reductions in overall transmission.
The role of mass drug administration (MDA) and the implementation of transmission reduction measures are essential to successfully control and eliminate a wide range of infectious diseases, such as: malaria , trachoma , schistosomiasis [5–7], onchocerciasis , and lymphatic filariasis . However, for diseases in which immunity to infection is acquired through repeated infections, it has been suggested that dramatically lowering transmission in a short time period may lead to unintended outcomes on the prevalence of infection and disease [3, 10–13]; if transmission is reduced, individuals who have not recently experienced an infection may have less immune protection than before transmission was reduced [6, 7, 12].
Immunity to trachoma acts on at least two levels: first, by reducing an individual’s bacterial load and therefore infectivity [14–16], and second, by reducing the duration of an individual’s infectious period with successive infections [17, 18]. As such, if the rate at which new infections are acquired is reduced, the rate at which immunity to infection develops will also be reduced. As an individual’s infectivity and duration of infectiousness are key components of the basic reproduction number (R 0), alterations at the population level of these parameters may impact the value of the effective reproduction number over time.
The possible adverse impact of MDA on R 0 and short term immunity to trachoma was explored in an analysis by Liu et al. . In this study a stochastic mathematical model was fitted to prevalence data from an MDA trial conducted across 32 communities in Tanzania [20, 21]. No significant change in the value of R 0 across the 3 year trial period was identified, suggesting little to no loss of population immunity during this time . However, if loss of population immunity were playing a role, a clear signal of increasing R 0 may only become apparent after several years of treatment, and the initial increase may be small. Data from a single community does not therefore provide sufficient evidence to suggest that this outcome is not a possibility in other communities.
The effect of reduced population immunity as a consequence of intensive treatment has also been hypothesised for genital C. trachomatis infection. Brunham et al. [22, 23] observed that following the introduction of an intensive treatment programme in Greater Vancouver, British Colombia, paradoxically, a monotonic decrease in genital chlamydial prevalence over time was not observed. Rather, they observed annual increases in rates of re-infection, with 14 % of all cases reported annually being re-infections [22, 23]. They postulated that this observation in part arose as a consequence of early treatment interfering with the development of natural immunity to infection. This phenomenon has been named The Arrested Immunity Hyposthesis , since it hinges upon the successful clearance of infection at the individual level, but the unintended prevention (or ‘arrest’) of the development of population immunity.
In this study, we use a published model of trachoma infection, which includes the development of population immunity, to explore the impact of treatment and transmission reduction measures on trachoma prevalence. We also investigate the possibility of adverse outcomes that may arise as MDA and transmission reduction measures are scaled up in endemic settings in order to achieve the GET2020 goal of eliminating blinding trachoma. This modelling study is complemented by a second study on trachoma in this issue, which focuses on the utility of active disease prevalence for the purposes of forecasting trachoma .
Model and assumptions
The effect of MDA on the prevalence of infection
We applied two different simulated MDA regimens to the modelled population; 3 and 10 annual rounds. Each MDA round had a population coverage level, c, of 85 % and antibiotic efficacy, e, of 95 % as in the study by Gambhir et al. . Those individuals in the population for whom an MDA round was successful cleared their infection completely and this was simulated here, as in previous studies, by shifting the cleared group (a proportion of the population c × e) from infected compartment i into susceptible compartment i on the ladder of infection.
Modelling reductions in transmission
The third GET2020 goal states that the F & E components of the SAFE strategy should be enhanced in order to help achieve the elimination of blinding trachoma by 2020. In this study we model enhancement of the F & E components as an instantaneous drop in the transmission parameter β when MDA is initiated. However, it remains challenging for trachoma treatment trials to identify and demonstrate the efficacy of F & E interventions; therefore, exactly how much enhanced F & E interventions may reduce transmission remains unknown. A recent meta-analysis suggested that the potential contributions of F & E to the reduced odds of trachoma infection could be very important . As such, we explore two values of transmission reduction (25 % and 50 %, one feasible and one optimistic; see e.g. ). The null assumption, i.e. no F &E impact, is considered here as those simulations that exclude F & E.
Distribution of the population by the number of infections experienced
One of the main drivers of a possible change in the transmission rate relates to the level of population immunity. Immunity to infection (but not re-infection) dictates the rate of recovery from an infection episode, and the bacterial load carried by an individual upon infection. Here we model these quantities as a function of the number of prior infections experienced, i (Fig. 1). We illustrate the changing distribution of the population according to the number of prior infections, following each of the simulated interventions we apply, by plotting a histogram of the proportion of individuals who have experienced i infections. We calculated this quantity for the susceptible population, since the resulting changes in the distribution are easier to see, though we confirmed that the overall population (i.e. susceptible + infected) shift is very similar.
Calculating the effective reproduction number over time
The summary parameter encapsulating the important aspects of transmissibility in the early stages of an outbreak is the basic reproduction number (R 0). However, R 0 would be the appropriate parameter to compute if the population were entirely susceptible and naïve to infection i.e. if there were no long term acquired immunity to infection in the population. Here, however, we are interested in the true transmissibility of trachoma infection in the presence of the current state of the population and so the relevant summary parameter is the effective reproduction number (R e ), which accounts for population immunity. Here, R e is a function of the current distribution of the population according to the number of prior infections experienced. We use the Next Generation Matrix method  to calculate R e for our ladder of infection model structure (see Additional file 1).
The effect of MDA on the prevalence of infection
At the therapeutic coverage and drug efficacy levels chosen, infection prevalence rebounded within the course of one year following each MDA round in the hyperendemic setting (Fig. 2c and f). Stopping treatment after 10 consecutive annual rounds resulted in no appreciable overall decline in prevalence (Fig. 2f) as infection re-bounded to pre-intervention levels before the next round of MDA had begun. However, infection prevalence was reduced more dramatically in the mesoendemic setting (Fig. 2b and e), and infection rebound occurred more slowly between treatments for the first 3 rounds of MDA. Cessation of treatment 10 years after commencement also resulted in the re-emergence of infection (Fig. 2b and e). When 10 MDA rounds were given, in the hyper- and mesoendemic settings, the rate of rebound of infection became faster with each subsequent treatment round (Fig. 2e and f). However, this observed rate of increase was only apparent in the mesoendemic community after 3 rounds of MDA had already occurred. The model suggested that in the hypoendemic case, infection could be effectively eliminated after 3 annual treatment rounds. However, a rebound following cessation of treatment was seen here due to the continuation of transmission at very low prevalences (<<1 %) in our (deterministic) model. Note that a deterministic model does not lend itself to the exploration of the possibility that infection could fade out due to random chance, nor can we assess the possibility that infection in the community can resurge when transmission is very low; this would require a stochastic modelling approach.
Distribution of the population by number of infections experienced
The population distributions following 10 simulated MDA rounds (Fig. 3, dark blue lines) show a marked shift toward the zero end of the prior infection spectrum. This shift is greater for the lower endemic settings and results in an increase in the average recovery rate and infection load experienced by infected members of the population, hence the rate at which immunity is acquired is slower.
Average duration of infection (in months) and infectivity (scaled between a high value of 1 and low of 0) calculated over the whole population at baseline and following 3 and 10 rounds of MDA, for each of the 3 endemic settings
Post 3 MDAs
Post 10 MDAs
Effective reproduction number over time
Transmission reduction and MDA together
In this study we hypothesise that successive MDA treatment rounds and rapid transmission reduction measures may lead to an increase in transmissibility of trachoma infection, and an increase in difficulty in controlling disease. This could be due to the gradual loss of immunity from the population following treatment. This effect was most pronounced for the lowest prevalence communities, in which transmission was low and control may be achievable despite it. However, in these communities, while control is feasible, elimination may become markedly more difficult over time if R e doubles over 20 years (as in Fig. 4). In hyperendemic communities, reductions in immunity result in a smaller transmissibility rise but, in the context of the extremely labour-intensive treatment schedules needed to achieve year-on-year declines in prevalence [14, 31, 32], even a marginal additional effort will be hard to maintain.
The increasingly rapid return of infection over time can be explained by the following process: first, sustained treatment prevents the population from progressing towards greater numbers of infections, which means that the population experiences fewer infections, on average; second, due to the slower rate of acquiring clearing immunity due to treatment and transmission reduction, individuals remain infected for longer periods of time, increasing the force of infection.
While our results in this study are theoretical, the rationale behind them has a sound biological basis. Recent work by Mitchell et al.  found that if protective immunity to schistosomiasis was short-lived, antibody levels declined to pre-intervention levels during or after MDA. However, if immunity was longer-lived and MDA was assumed to reduce transmission, a large over-shoot in measured egg count was observed. This modelling work was supported by antibody data suggesting MDA and transmission reduction may disrupt the development of protective immunity or alter existing population immunity .
The hypothesis presented in this article has been quantitatively tested just once for trachoma, to our knowledge, within a mesoendemic community, by Liu et al. . While the authors did not identify a significant change in R e over the 3 year period analysed, the analysis presented here suggests that a strong signal of increase in R e may only become apparent after several years, and that its initial increase may be small.
Our simulated MDA assumes random allocation of doses in the population with each treatment, while a persistently untreated group of individuals is also a possibility. In the latter case, it is likely that the value of R e would increase more slowly and to a lesser overall extent due to a more rapid reseeding of infection from the untreated group into the wider population following each treatment round.
The adverse effect we find applies to communities in which MDA is introduced in isolation, but it may be exacerbated when dramatic transmission reduction measures are rapidly implemented. Such an outcome has previously been suggested for malaria [10, 12]. In this instance it is expected that a higher number of severe disease cases will be observed immediately following the reduction in transmission, primarily as a result of the loss of population immunity. Furthermore, epidemiological surveillance data in genital chlamydia infection has also shown empirical evidence of this effect [22, 23]. It was reported that re-infection rates following the introduction of an infection control programme resulted in a 4.6 % per year re-infection rate increase during the period of study from 1989–2003 . These findings were complemented with a mathematical transmission model suggesting that early treatment of infection increased the population’s susceptibility to re-infection . However, Vickers et al.  suggested that the increased rates of re-infection in Canada could mainly be attributable to an increase in testing volume, implying that The Arrested Immunity Hypothesis had a less significant role on the transmission dynamics than previously reported .
To date, the analysis of serological data collected through trachoma surveillance has been very limited [34, 35]. Martin et al.  fitted a catalytic model to serological data in order to identify when changes in transmission intensity within a Tanzanian community occurred. The authors used a binary cut-off to determine whether individuals in the study were seropositive or seronegative and, during the surveillance period, they did not identify any individuals who seroreverted, suggesting no loss of population immunity. However, the use of a binary cut-off to define individuals as seropositive or seronegative can mask changes in the antibody titres that may occur over time, meaning that even if an individual’s titre has declined dramatically, if it does not fall below the cut-off threshold, they will still be classified as seropositive. Indeed, Goodhew et al.  showed that there was evidence of a significant decline in trachoma antigens for nearly all age groups 6 months after MDA was applied. Anti-trachoma antibodies are likely to be associated with protection although the exact relationship is poorly understood. Antibody titers may decrease over time while an individual remains seropositive leading to a likely decrease in protection over time.
Therefore, while the effects presented here remain to be substantiated with data from treatment and transmission reduction trachoma trials, we suggest the effect seen for genital chlamydia and schistosomiasis should be motivation to design trials which include these outcomes.
Implications for study design
In this article we have considered the impact of MDA and transmission reduction interventions across the whole community; however, the data analysed by Liu et al. in  were collected from 0–5 year olds. It is possible that, since young children experience the most ‘severe infections’ with respect to having the highest bacterial loads and slower rates of recovery, shifts in population level immunity may not manifest themselves in this age group. However, longer infection durations may be seen in older age groups which increasingly consist of individuals with less mature immunity as a result of declines in transmission; this older population was not observed in the analysis by Liu et al. . Moreover, studies previously conducted to examine loss of immunity to C. trachomatisremain limited to the analysis of a small number of communities [22, 36], potentially limiting their power to identify loss of population immunity. This suggests that in order to monitor whether the GET2020 goals are being achieved, larger studies that also monitor the infection and disease status of older individuals in the population will be important to ensure that loss of immunity through transmission reduction does not help to sustain infection within the community.
It may be that a combination of transmission-enhancing and reducing (so called Allee [37, 38]) effects will determine the trajectory of the prevalence over time close to elimination . Lietman et al. demonstrated that a common linear hazard of infection term in a mechanistic model is not sufficient to describe trachoma infection rebound dynamics at low prevalences, and they accounted for this using a nonlinear adjustment to the hazard . It is incumbent upon modellers and quantitative parasitologists to help devise field studies to measure the rate of return of infection and disease in at least two separate age groups; these studies could determine whether density dependent effects are playing a role and what their relative contribution is.
Implications for the GET2020 goals
The results we present apply directly to the GET2020 goals relating to the reduction of active disease (TF) and disease sequelae (TT): both MDA and transmission reduction (e.g. F & E) interventions may both result in rises in rates of return of infection and disease over time due to the loss of population immunity, making the achievement of the TF and TT goals more challenging.
In addition, we show that this effect may be worse for lower-endemic communities. However, we note that the model used in this analysis was deterministic, and therefore it is not ideally suited to assess the stochastic fade-out and elimination of infection within a community. Therefore the perverse outcome observed in lower transmission settings may not be a problem if infection fades out and does not eventually re-emerge in a community, as it does in our deterministic model. A reason that the observed effect is most exacerbated within the hypoendemic community is that we have assumed immunity to infection develops exponentially and, as such, larger changes in rates of recovery and infectivity will be seen when people within the community experience a low number of infections both at baseline and following MDA.
We also show the effect may also be worse for currently highly-endemic communities in which intensive SAFE programmes are imposed, as dictated by the third GET2020 goal, which states that the F & E components of the SAFE strategy should be enhanced. However, by reducing the frequency at which individuals become infected through transmission reduction and MDA, this will ultimately result in lower equilibrium levels of infection prevalence and ultimately a lower prevalence of disease sequelae due to individuals experiencing fewer infections over their lifetime.
The role of acquired immunity to trachoma remains poorly understood, but modelling the dynamics associated with the loss and gain of population immunity is essential if we are to account for outcomes that, perversely, may result in transmissibility increases as a result of transmission reduction measures. Changes in population immunity to infection as a result of intensive transmission reduction measures may frustrate the achievement of the GET2020 goals, and field trials need to be designed in order to monitor and minimise the chance and effects of these outcomes. This may also mean that longer-term post-validation surveillance is required to ensure the incidence of infection does not begin to increase over time, following achievement of the GET2020 goals. However, it is likely the cost of intermittent surveillance will be justified if we want to achieve the long-term elimination of blinding trachoma.
AP and MG gratefully acknowledge funding of the NTD Modelling Consortium by the Bill and Melinda Gates Foundation in partnership with the Task Force for Global Health. The views, opinions, assumptions or any other information set out in this article are solely those of the authors.
MG also acknowledges funding from the Australian NHMRC and Monash University.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- WHO. Global WHO Alliance for the Elimination of Blinding Trachoma by 2020. Wkly Epidemiol Rec. 2012;87(17):161–8.Google Scholar
- Callahan K, Ogale YP, Palmer SL, Emerson PM, Hopkins DR, Withers PC, et al. Trachoma Control as a Vehicle Toward International Development and Achievement of the Millennium Development Goals. PLoS Negl Trop Dis. 2014;8(9):e3137.PubMed CentralView ArticlePubMedGoogle Scholar
- Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ, et al. The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS One. 2011;6(5):e20179.PubMed CentralView ArticlePubMedGoogle Scholar
- Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med. 1999;5(5):572–6.View ArticlePubMedGoogle Scholar
- Mitchell KM, Mutapi F, Mduluza T, Midzi N, Savill NJ, Woolhouse MEJ. Predicted Impact of Mass Drug Administration on the Development of Protective Immunity against Schistosoma haematobium. PLoS Negl Trop Dis. 2014;8(7):e3059.PubMed CentralView ArticlePubMedGoogle Scholar
- Sokolow SH, Huttinger E, Jouanard N, Hsieh MH, Lafferty KD, Kuris AM, et al. Reduced transmission of human schistosomiasis after restoration of a native river prawn that preys on the snail intermediate host. Proc Natl Acad Sci. 2015;112(31):9650–5.View ArticlePubMedGoogle Scholar
- Grimes JE, Croll D, Harrison WE, Utzinger J, Freeman MC, Templeton MR. The roles of water, sanitation and hygiene in reducing schistosomiasis: a review. Parasites Vectors. 2015;8:156.PubMed CentralView ArticlePubMedGoogle Scholar
- Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum N-K, Hopkins A, et al. Reaching the London Declaration on Neglected Tropical Diseases Goals for Onchocerciasis: An Economic Evaluation of Increasing the Frequency of Ivermectin Treatment in Africa. Clin Infect Dis. 2014;59(7):923–32.PubMed CentralView ArticlePubMedGoogle Scholar
- Bockarie MJ, Deb RM. Elimination of lymphatic filariasis: do we have the drugs to complete the job? Curr Opin Infect Dis. 2010;23(6):617–20.View ArticlePubMedGoogle Scholar
- Snow RW, Marsh K. Will reducing Plasmodium falciparum transmission alter malaria mortality among African children? Parasitol Today. 1995;11(5):188–90.View ArticleGoogle Scholar
- Snow RW, Omumbo JA, Lowe B, Molyneux CS, Obiero JO, Palmer A, et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet (London, England). 1997;349(9066):1650–4.View ArticleGoogle Scholar
- Snow RW, Marsh K. The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol. 2002;52:235–64.View ArticlePubMedGoogle Scholar
- Trape JF, Rogier C. Combating malaria morbidity and mortality by reducing transmission. Parasitology today (Personal ed). 1996;12(6):236–40.View ArticleGoogle Scholar
- Burton MJ, Holland MJ, Makalo P, Aryee EAN, Alexander NDE, Sillah A, et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet. 2005;365(9467):1321–8.View ArticlePubMedGoogle Scholar
- Solomon AW, Holland MJ, Burton MJ, West SK, Alexander NDE, Aguirre A, et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet. 2003;362(9379):198–204.View ArticlePubMedGoogle Scholar
- Faal N, Bailey RL, Jeffries D, Joof H, Sarr I, Laye M, et al. Conjunctival FOXP3 Expression in Trachoma: Do Regulatory T Cells Have a Role in Human Ocular Chlamydia trachomatis Infection? PLoS Med. 2006;3(8):e266.PubMed CentralView ArticlePubMedGoogle Scholar
- Grassly NC, Ward ME, Ferris S, Mabey DC, Bailey RL. The Natural History of Trachoma Infection and Disease in a Gambian Cohort with Frequent Follow-Up. PLoS Negl Trop Dis. 2008;2:12.View ArticleGoogle Scholar
- Bailey R, Duong T, Carpenter R, Whittle H, Mabey D. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect. 1999;123(03):479–86.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu FC, Porco TC, Ray KJ, Bailey RL, Mkocha H, Munoz B, et al. Assessment of Transmission in Trachoma Programs over Time Suggests No Short-Term Loss of Immunity. PLoS Negl Trop Dis. 2013;7:7.View ArticleGoogle Scholar
- Harding-Esch EM, Edwards T, Mkocha H, Munoz B, Holland MJ, Burr SE, et al. Trachoma Prevalence and Associated Risk Factors in The Gambia and Tanzania: Baseline Results of a Cluster Randomised Controlled Trial. PLoS Negl Trop Dis. 2010;4(11):e861.PubMed CentralView ArticlePubMedGoogle Scholar
- Stare D, Harding-Esch E, Munoz B, Bailey R, Mabey D, Holland M, et al. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia. Ophthalmic Epidemiol. 2011;18(1):20–9.View ArticlePubMedGoogle Scholar
- Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis. 2005;192(10):1836–44.View ArticlePubMedGoogle Scholar
- Brunham RC, Rekart ML. The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm Dis. 2008;35(1):53–4.View ArticlePubMedGoogle Scholar
- Liu F, Porco TC, Amza A, Kadri B, Nassirou B, West SK, et al. Short-term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites Vectors. 2015.Google Scholar
- Gambhir M, Basanez MG, Turner F, Kumaresan J, Grassly NC. Trachoma: transmission, infection, and control. Lancet Infect Dis. 2007;7(6):420–7.View ArticlePubMedGoogle Scholar
- Gambhir M, Basanez MG, Burton MJ, Solomon AW, Bailey RL, Holland MJ, et al. The development of an age-structured model for trachoma transmission dynamics, pathogenesis and control. PLoS Negl Trop Dis. 2009;3(6):e462.PubMed CentralView ArticlePubMedGoogle Scholar
- West SK, Munoz B, Mkocha H, Hsieh YH, Lynch MC. Progression of active trachoma to scarring in a cohort of Tanzanian children. Ophthalmic Epidemiol. 2001;8(2–3):137–44.View ArticlePubMedGoogle Scholar
- Gambhir M, Basanez MG, Blake IM, Grassly NC. Modelling trachoma for control programmes. Adv Exp Med Biol. 2010;673:141–56.View ArticlePubMedGoogle Scholar
- Stocks ME, Ogden S, Haddad D, Addiss DG, McGuire C, Freeman MC. Effect of water, sanitation, and hygiene on the prevention of trachoma: a systematic review and meta-analysis. PLoS Med. 2014;11(2):e1001605.PubMed CentralView ArticlePubMedGoogle Scholar
- Diekmann O, Heesterbeek JA, Roberts MG. The construction of next-generation matrices for compartmental epidemic models. J R Soc Interface. 2010;7(47):873–85.PubMed CentralView ArticlePubMedGoogle Scholar
- West SK, Munoz B, Mkocha H, Holland MJ, Aguirre A, Solomon AW, et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet (London, England). 2005;366(9493):1296–300.View ArticleGoogle Scholar
- Lakew T, House J, Hong KC, Yi E, Alemayehu W, Melese M, et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Negl Trop Dis. 2009;3(2):e376.PubMed CentralView ArticlePubMedGoogle Scholar
- Vickers D, Osgood N. Current crisis or artifact of surveillance: insights into rebound chlamydia rates from dynamic modelling. BMC Infect Dis. 2010;10(1):1–10.View ArticleGoogle Scholar
- Goodhew E, Morgan S, Switzer A, Munoz B, Dize L, Gaydos C, et al. Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration. BMC Infect Dis. 2014;14(1):1–8.View ArticleGoogle Scholar
- Martin DL, Bid R, Sandi F, Goodhew EB, Massae PA, Lasway A, et al. Serology for Trachoma Surveillance after Cessation of Mass Drug Administration. PLoS Negl Trop Dis. 2015;9(2):e0003555.PubMed CentralView ArticlePubMedGoogle Scholar
- Atik B, Thanh TT, Luong VQ, Lagree S, Dean D. Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA. 2006;296(12):1488–97.View ArticlePubMedGoogle Scholar
- Chidambaram JD, Lee DC, Porco TC, Lietman TM. Mass antibiotics for trachoma and the Allee effect. Lancet Infect Dis. 2005;5(4):194–6.View ArticlePubMedGoogle Scholar
- Lietman TM, Gebre T, Ayele B, Ray KJ, Maher MC, See CW, et al. The epidemiological dynamics of infectious trachoma may facilitate elimination. Epidemics. 2011;3(2):119–24.View ArticlePubMedGoogle Scholar
- Gambhir M, Singh BK, Michael E. The Allee effect and elimination of neglected tropical diseases: a mathematical modelling study. Adv Parasitol. 2015;87:1–31.View ArticlePubMedGoogle Scholar